The Onchocerciasis (River Blindness) drugs in development market research report provides comprehensive information on the therapeutics under development for Onchocerciasis (River Blindness), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Onchocerciasis (River Blindness). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Onchocerciasis (River Blindness) and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Onchocerciasis (River Blindness) by eight companies/universities/institutes. The top development phase for Onchocerciasis (River Blindness) is preclinical with four drugs in that stage. The Onchocerciasis (River Blindness) pipeline has seven drugs in development by companies and two by universities/ institutes. Some of the companies in the Onchocerciasis (River Blindness) pipeline products market are: Pai Life Sciences, Lyndra Therapeutics and Helix Biogen Institute.

The key targets in the Onchocerciasis (River Blindness) pipeline products market include 16S Ribosomal RNA (16S rRNA).

The key mechanisms of action in the Onchocerciasis (River Blindness) pipeline product include 16S Ribosomal RNA (16S rRNA) Inhibitor with one drug in Preclinical. The Onchocerciasis (River Blindness) pipeline products include one routes of administration with the top ROA being Oral and three key molecule types in the Onchocerciasis (River Blindness) pipeline products market including Small Molecule, and Subunit Vaccine.

Onchocerciasis (River Blindness) overview

Onchocerciasis, or river blindness, is a neglected tropical disease (NTD) caused by the parasitic worm Onchocerca volvulus. It is transmitted through repeated bites by blackflies of the genus Simulium. The disease is called river blindness because the blackfly that transmits the infection lives and breeds near fast flowing streams and rivers. The infection can result in visual impairment and sometimes blindness. Also, onchocerciasis can cause skin disease, itching, rashes, or nodules under the skin.

For a complete picture of Onchocerciasis (River Blindness)’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.